公开(公告)号：US06958339B2

公开(公告)日：2005-10-25

申请号：US09773736

申请日：2001-02-02

Applicant: Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizo Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Jun Ishikawa ,  Makoto Takeuchi

Inventor： Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizo Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Jun Ishikawa ,  Makoto Takeuchi

IPC: A61K31/4155 ,  A61K31/416 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/538 ,  C07D231/12 ,  C07D231/14 ,  C07D401/12 ,  C07D403/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/02 ,  C07D417/02 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D521/00 ,  A61K31/415

CPC classification number: C07D231/12 ,  C07D231/14 ,  C07D233/56 ,  C07D249/08 ,  C07D401/12 ,  C07D403/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention is directed to drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, wherein each substituent is defined in the specification. The present invention also relates to a pharmaceutical composition containing an effective amount of the compound of formula (I) and a pharmaceutically effective carrier.The present invention further relates to methods of treatment of diseases associated with calcium release-activated calcium channels, diseases associated with IL-2 production, and methods of treatment of allergic, inflammatory or auto-immune diseases.

Abstract translation: 本发明涉及具有钙释放激活的钙通道抑制作用的药物，特别是由以下通式（I）表示的吡唑衍生物，特别是含有上述的钙释放激活的钙通道抑制剂的药物组合物 化合物作为活性成分，其中每个取代基在说明书中定义。 本发明还涉及含有有效量的式（I）化合物和药学有效载体的药物组合物。 本发明还涉及治疗与钙释放激活的钙通道有关的疾病，与IL-2产生有关的疾病，以及治疗过敏性，炎性或自身免疫性疾病的方法。

公开(公告)号：US06938668B2

公开(公告)日：2005-09-06

申请号：US10242382

申请日：2002-09-12

Applicant: Forrest D. Whicher ,  Makoto Takeuchi

Inventor： Forrest D. Whicher ,  Makoto Takeuchi

IPC: A61L27/00 ,  A61F2/00 ,  A61F2/02 ,  A61F2/24 ,  A61F2/82 ,  A61L31/02 ,  C23C14/00 ,  C23C14/14 ,  B22D23/00

CPC classification number: C23C14/34 ,  A61F2/82 ,  A61F2210/0014 ,  A61F2240/001 ,  A61F2310/00017 ,  A61F2310/00023 ,  A61F2310/00029 ,  A61F2310/00059 ,  A61F2310/00071 ,  A61F2310/00089 ,  A61F2310/00095 ,  A61F2310/00113 ,  A61F2310/00131 ,  A61F2310/00149 ,  A61F2310/00155 ,  A61L31/022 ,  C23C14/0005 ,  C23C14/562

Abstract: A method of forming a medical device, the method including the steps of providing a substrate, depositing a metallic layer on the substrate by a vapor deposition process, and removing the metallic layer from the substrate. The metallic layer thus removed is the medical device or serves as a basis for forming the medical device. In another aspect, the present invention includes a medical device formed by the process of the present invention.

Abstract translation: 一种形成医疗装置的方法，所述方法包括以下步骤：提供基底，通过气相沉积工艺在所述基底上沉积金属层，以及从所述基底去除所述金属层。 这样除去的金属层是医疗装置，或用作形成医疗装置的基础。 另一方面，本发明包括通过本发明的方法形成的医疗装置。

公开(公告)号：US06882517B2

公开(公告)日：2005-04-19

申请号：US10724229

申请日：2003-12-01

Applicant: Tamotsu Tano ,  Takashi Oyama ,  Akinori Mogami ,  Makoto Takeuchi ,  Hiroshi Kobayashi ,  Yukinori Kude

Inventor： Tamotsu Tano ,  Takashi Oyama ,  Akinori Mogami ,  Makoto Takeuchi ,  Hiroshi Kobayashi ,  Yukinori Kude

IPC: C01B31/02 ,  C10B55/02 ,  H01G9/00 ,  H01G11/22 ,  H01G11/24 ,  H01G11/32 ,  H01G11/34 ,  H01G11/38 ,  H01G11/42 ,  H01G11/44 ,  H01G11/84 ,  H01G11/86 ,  H01M4/96

CPC classification number: H01G9/155 ,  H01M4/583 ,  H01M4/96 ,  Y02E60/13 ,  Y10T428/30

Abstract: A raw material composite 10 for a carbon material used in an electric double layer capacitor contains microcrystalline carbon having a layered crystal structure similar to graphite, and is formed a carbon material for an electric double layer capacitor by undergoing an activation treatment. Here, the raw material composite is characterized in that a Hardgrove grindability index HGI defined by ASTMD-409-71 is 50 or above, an interlayer distance d002 of the microcrystalline carbon determined by an X-ray diffraction method is 0.343 NM or below, and a crystallite size Lc002 of the microcrystalline carbon determined by the X-ray diffraction method is 3.0 nm or below.

Abstract translation: 用于双电层电容器中的碳材料的原料复合材料10包含具有与石墨类似的层状晶体结构的微晶碳，并且通过进行活化处理形成双电层电容器的碳材料。 这里，原料复合体的特征在于，由ASTMD-409-71定义的Hardgrove研磨性指数HGI为50以上，通过X射线衍射测定的微晶碳的层间距离d 002 方法为0.343NM以下，通过X射线衍射法测定的微晶碳的微晶尺寸Lc 002℃为3.0nm以下。

公开(公告)号：US20050064539A1

公开(公告)日：2005-03-24

申请号：US10480790

申请日：2002-06-14

Applicant: Yasunori Chiba ,  Yoshifumi Jigami ,  Hitoshi Sakuraba ,  Kazuo Kobayashi ,  Makoto Takeuchi ,  Yoriko Takeuchi

Inventor： Yasunori Chiba ,  Yoshifumi Jigami ,  Hitoshi Sakuraba ,  Kazuo Kobayashi ,  Makoto Takeuchi ,  Yoriko Takeuchi

IPC: C12N15/09 ,  A61K36/064 ,  A61K38/00 ,  A61K38/17 ,  A61P9/00 ,  A61P9/14 ,  A61P13/12 ,  A61P17/00 ,  A61P19/00 ,  A61P27/02 ,  A61P43/00 ,  C08B37/00 ,  C12N9/10 ,  C12N9/40 ,  C12P21/00 ,  C12P21/06 ,  C12N1/18

CPC classification number: C12P21/005 ,  A61K36/064 ,  A61K38/17 ,  C12N9/1051 ,  A61K2300/00

Abstract: A process for producing a lysosomal enzyme having a mannose-6-phosphate-containing acidic sugar chain, wherein the process comprising: culturing in a medium yeast cells obtained by introducing a lysosomal enzyme gene into a sugar chain biosynthetic enzyme gene mutant strain of yeast, collecting a lysosomal enzyme having a phosphate-containing sugar chain from the culture, and then treating the enzyme with α-mannosidase; and pharmaceutical compositions for treatment of human lysosomal enzyme deficiencies produced by the process. The genetic engineering technique using the yeast according to the present invention allows large-amount and high-purity production of a glycoprotein having a phosphate-containing acidic sugar chain which can serve as a labeling marker for transporting into lysosomes in cells of mammals such as human. The glycoprotein having a phosphate-containing acidic sugar chain according to the invention may be utilized as a drug effective in treatment of human lysosomal enzyme deficiencies, etc.

Abstract translation: 一种生产含有甘露糖-6-磷酸的酸性糖链的溶酶体酶的方法，其中所述方法包括：在通过将溶酶体酶基因导入酵母的糖链生物合成酶基因突变菌株获得的培养基中培养酵母， 从培养物中收集含有含磷酸盐糖链的溶酶体酶，然后用α-甘露糖苷酶处理酶; 以及用于治疗由该方法产生的人溶酶体酶缺陷的药物组合物。 使用根据本发明的酵母的基因工程技术允许大量和高纯度产生具有含磷酸盐的酸性糖链的糖蛋白，其可以用作在诸如人类的哺乳动物的细胞中输送到溶酶体的标记标记 。 具有根据本发明的含磷酸盐酸性糖链的糖蛋白可以用作治疗人溶酶体酶缺陷等的药物。

公开(公告)号：US20050053507A1

公开(公告)日：2005-03-10

申请号：US10914644

申请日：2004-08-10

Applicant: Makoto Takeuchi ,  Tetsuzo Ukai ,  Masaaki Tokuda

Inventor： Makoto Takeuchi ,  Tetsuzo Ukai ,  Masaaki Tokuda

IPC: F04C18/02 ,  F04C28/26 ,  F01C1/02 ,  F01C1/063 ,  F04C18/00

CPC classification number: F04C28/26 ,  F04C18/0215 ,  F04C18/0261 ,  F04C18/0276 ,  F04C18/088

Abstract: A scroll compressor includes a first scroll and a second scroll. The first scroll has a step portion that separates an elevated portion and a recessed portion of a surface of the first scroll. A spiral wall of the second scroll has a step that separates an elevated portion and a recessed portion of the wall. A first bypass hole is provided in the elevated portion of the surface of the first scroll. A second bypass hole is provided in the recessed portion of the surface of the first scroll. The second bypass hole is within 360 degrees toward a center of the spiral of the first scroll from an outer end of the spiral. The first bypass hole is within 360 degrees from the second bypass hole toward the center of the spiral.

Abstract translation: 涡旋压缩机包括第一涡旋件和第二涡旋件。 第一涡旋件具有分离第一涡旋件的表面的升高部分和凹部的台阶部分。 第二涡卷的螺旋壁具有分隔壁的升高部分和凹陷部分的台阶。 第一旁通孔设置在第一涡旋盘的表面的升高部分中。 第二旁通孔设置在第一涡旋盘的表面的凹部中。 第二旁通孔从螺旋的外端朝向第一涡旋盘的螺旋的中心360度内。 第一旁通孔与第二旁通孔朝向螺旋中心360度以内。

公开(公告)号：US06777396B2

公开(公告)日：2004-08-17

申请号：US09864251

申请日：2001-05-25

Applicant: Izuru Shinzato ,  Hiroyuki Sato ,  Yasuhiko Toride ,  Makoto Takeuchi

Inventor： Izuru Shinzato ,  Hiroyuki Sato ,  Yasuhiko Toride ,  Makoto Takeuchi

IPC: A61K317052

CPC classification number: A23K50/60 ,  A23K20/142 ,  A23K20/153

Abstract: A composition for livestock feed, comprising a feed for livestock and at least two additives selected from the group consisting of nucleic acid, glutamine and glutamic acid; and a method for increasing body weight gain efficiency and feed efficiency in livestock, comprising administering the above composition for livestock feed to livestock.

Abstract translation: 一种用于家畜饲料的组合物，其包含用于家畜的饲料和至少两种选自核酸，谷氨酰胺和谷氨酸的添加剂; 以及用于提高家畜体重增加效率和饲料效率的方法，其包括将上述饲料用于家畜饲料的组合物施用。

公开(公告)号：US06740662B1

公开(公告)日：2004-05-25

申请号：US10111077

申请日：2002-04-19

Applicant: Masahiro Iwata ,  Noriyuki Kawano ,  Tomofumi Takuwa ,  Ryota Shiraki ,  Miki Kobayashi ,  Makoto Takeuchi

Inventor： Masahiro Iwata ,  Noriyuki Kawano ,  Tomofumi Takuwa ,  Ryota Shiraki ,  Miki Kobayashi ,  Makoto Takeuchi

IPC: A61K31435

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: 2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, —X—R6, at the 3-position and a cyclic substituent, R5, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.

Abstract translation: 2-氧代-1,2-二氢-1,8-二氮杂萘衍生物，其特征在于在3-位具有特定取代基-X-R 6，在4-位具有环取代基R 5; 或其盐。 衍生物和盐可​​用作药物，特别是与PDE IV相关的呼吸道疾病的预防或治疗剂。

公开(公告)号：US06348480B1

公开(公告)日：2002-02-19

申请号：US09529131

申请日：2000-04-07

Applicant: Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizou Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Yoshinori Okamoto ,  Jun Ishikawa ,  Makoto Takeuchi

Inventor： Hirokazu Kubota ,  Yasuhiro Yonetoku ,  Keizou Sugasawa ,  Masashi Funatsu ,  Souichirou Kawazoe ,  Akira Toyoshima ,  Yoshinori Okamoto ,  Jun Ishikawa ,  Makoto Takeuchi

IPC: C07D41710

CPC classification number: C07D231/12 ,  C07D231/14 ,  C07D233/56 ,  C07D249/08 ,  C07D401/12 ,  C07D403/12 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention is directed to drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, wherein each substituent is defined in the specification. The present invention also relates to a pharmaceutical composition containiing an effective amount of the compound of formula (I) and a pharmaceutically effective carrier. The present invention further relates to methods of treatment of diseases associated with calcium release-activated calcium channels, diseases associated with IL-2 production, and methods of treatment of allergic, inflammatory or auto-immune diseases.

Abstract translation: 本发明涉及具有钙释放激活的钙通道抑制作用的药物，特别是由以下通式（I）表示的吡唑衍生物，特别是含有上述的钙释放激活的钙通道抑制剂的药物组合物 化合物作为活性成分，其中每个取代基在本说明书中定义。本发明还涉及含有有效量的式（I）化合物和药学有效载体的药物组合物。本发明还涉及 治疗与钙释放激活的钙通道相关的疾病，与IL-2产生相关的疾病，以及治疗过敏性，炎性或自身免疫性疾病的方法。

公开(公告)号：US06295269B1

公开(公告)日：2001-09-25

申请号：US09017753

申请日：1998-02-03

Applicant: Makoto Takeuchi ,  Kazuhiko Kitamura

Inventor： Makoto Takeuchi ,  Kazuhiko Kitamura

IPC: G11B2300

CPC classification number: F16F15/363 ,  G01M1/36 ,  G11B19/2009 ,  G11B19/2027 ,  G11B25/043

Abstract: A weight member is attached to a rotor so as to forcibly offset a center of gravity of a rotor from a rotating axis, centrifugal force moves two movable weight members to appropriate positions for canceling the unbalance due to the center of gravity offset from the rotating axis, and stoppers restrict the movement of the two movable weight members in a sectoral area opposite to the center of gravity so that the rotor is free from vibrations due to the characteristic angular velocity.

Abstract translation: 配重部件被安装在转子上，从而将转子的重心从旋转轴线上强制地偏移，离心力将两个可动配重件移动到合适的位置，以消除由于重心偏离旋转轴线的不平衡 并且止动件限制两个可移动重量件在与重心相反的扇形区域中的移动，使得转子由于特征角速度而没有振动。

公开(公告)号：US06174896B1

公开(公告)日：2001-01-16

申请号：US09312392

申请日：1999-05-14

Applicant: Makoto Takeuchi ,  Ryo Naito ,  Masahiko Hayakawa ,  Yoshinori Okamoto ,  Yasuhiro Yonetoku ,  Ken Ikeda ,  Yasuo Isomura

Inventor： Makoto Takeuchi ,  Ryo Naito ,  Masahiko Hayakawa ,  Yoshinori Okamoto ,  Yasuhiro Yonetoku ,  Ken Ikeda ,  Yasuo Isomura

IPC: A61K31439

CPC classification number: C07D221/12 ,  C07D453/02 ,  C09K19/3444

Abstract: Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. The compound has an antagonistic effect on muscarinic M3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.

Abstract translation: 由通式（I）表示的喹喔啉衍生物，其盐，N-氧化物或季铵盐，以及含有它们的药物组合物。该化合物对毒蕈碱M3受体具有拮抗作用，可用作泌尿系统的预防或治疗 疾病，呼吸系统疾病或消化系统疾病。